HomeSYGGF • OTCMKTS
add
Synairgen plc
Previous close
$0.050
Year range
$0.023 - $0.12
Market cap
9.77M GBP
Avg Volume
710.00
P/E ratio
-
Dividend yield
-
Primary exchange
LON
Market news
Financials
Income Statement
Revenue
Net income
| (GBP) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.95M | -29.14% |
Net income | -1.63M | 31.28% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.95M | 28.75% |
Effective tax rate | 10.92% | — |
Balance Sheet
Total assets
Total liabilities
| (GBP) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.59M | -19.19% |
Total assets | 10.64M | -43.12% |
Total liabilities | 1.08M | -60.69% |
Total equity | 9.56M | — |
Shares outstanding | 201.37M | — |
Price to book | 1.00 | — |
Return on assets | -45.90% | — |
Return on capital | -51.07% | — |
Cash Flow
Net change in cash
| (GBP) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -1.63M | 31.28% |
Cash from operations | -1.84M | 30.36% |
Cash from investing | 882.00K | 88,100.00% |
Cash from financing | — | — |
Net change in cash | -962.50K | 63.64% |
Free cash flow | -1.13M | 24.89% |
About
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.
Richard Marsden was appointed chief executive officer in September 2009. Wikipedia
Founded
2003
Website
Employees
36
